2023 parent results
Feb 13 (Reuters)-
Sosei Group Corp
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2023 Dec 31, 2022 Dec 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 5.02 1.12
(+348.4 pct) (+35.9 pct)
Operating loss 335 mln loss 1.10
Recurring loss 3.30 loss 1.59
Net loss 3.29 loss 1.50
EPS loss 39.81 yen loss 18.30 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Sosei Group Corp.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up